Latham & Watkins and Davis Polk advise on Coherus BioSciences $120 million public offering
Latham & Watkins provided counsel to Redwood City-based biosimilar company Coherus BioSciences Inc. in its proposed $120 million public offering. The company is selling 4,137,931 shares of common stock at a price of $29 per share.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
